Bioolase: Neues Patent (Fettabsaugung) - 500 Beiträge pro Seite
eröffnet am 27.07.01 12:06:20 von
neuester Beitrag 28.07.01 21:22:20 von
neuester Beitrag 28.07.01 21:22:20 von
Beiträge: 2
ID: 445.503
ID: 445.503
Aufrufe heute: 0
Gesamt: 351
Gesamt: 351
Aktive User: 0
ISIN: US0909112072 · WKN: A2JLZ6
0,1869
EUR
-32,79 %
-0,0912 EUR
Letzter Kurs 29.04.22 Tradegate
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
1,5900 | +207,96 | |
0,5100 | +134,48 | |
0,7000 | +75,00 | |
3,0000 | +42,18 | |
15,348 | +19,53 |
Wertpapier | Kurs | Perf. % |
---|---|---|
0,8209 | -22,56 | |
1,3500 | -25,62 | |
0,7800 | -29,73 | |
2.849,50 | -83,34 | |
5,0100 | -90,93 |
BIOLASE Granted New Waterlase Cosmetic Surgery Patent
SAN CLEMENTE, Calif., July 26 /PRNewswire/ -- BIOLASE Technology, Inc.
(Nasdaq: BLTI - news), announced today that it was granted a significant new patent
to use its HydroKinetic® technology for liposuction and other cosmetic soft
tissue procedures.
Since HydroKinetic technology uses a laser combined with
atomized water spray, BIOLASE expects the system in this patent to have
significant benefits over conventional liposuction, such as reduced bleeding,
less bruising, less trauma and less post-operative discomfort.
When compared
with other possible laser methods, HydroKinetics is expected to provide more effective cutting and removal of tissue without thermal damage, char or
potentially harmful smoke.
According to the American Society for Aesthetic Plastic Surgery,
lipoplasty (liposuction) was the most popular and fastest-growing surgical
cosmetic procedure, increasing 31% from 1999 to 2000 for a total of
376,633 procedures in the United States.
Cosmetic eyelid surgery ranked
second among surgical procedures, up 16% to 212,133 procedures.
Breast
augmentation was third, rising 6% to 203,310 procedures.
Ioana Rizoiu, the named inventor and vice president of clinical research
at BIOLASE, commented, ``This is both a device and method patent.
It is very
broad in regards to electromagnetic energy including the entire spectrum of
laser wavelengths and any and all sources of radiation, including all RF and
electrical sources.
This patent was filed as part of our overall, long-term
patent strategy and is only one of many others pending approval.``
Jeffrey W. Jones, BIOLASE CEO and president, explained, ``This innovative
patent expands the intellectual property of our HydroKinetic technology and is
an important addition to our overall patent portfolio.
This is another
important step to expand the intellectual property for the numerous fields and
applications of our core technology.
At this time, BIOLASE intends to keep
its current focus on dentistry.
We will explore the feasibility of alliances
and licensing for certain applications and expanded development.``
BIOLASE Technology, Inc. (http://www.biolase.com) is an advanced medical
technology company which possesses and develops advanced dental, cosmetic,
aesthetic and surgical products, including Waterlase(TM) (HydroKinetic®)
surgical cutting systems and other advanced laser and non-laser products for
the medical market.
The company`s products incorporate patented and
patent-pending technologies in the pursuit of painless surgery.
BIOLASE is
the world leader in painless hard and soft tissue dental laser technology.
The matters discussed in this news release include forward-looking
statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results
anticipated in such forward-looking statements.
Such risks, uncertainties and other factors include, but are not limited to, the effect of actions of third
parties, including governmental officials, the timely development and acceptance of new products, the impact of competitive products and pricing,
and other risks detailed from time-to-time in the Company`s filings with the
Securities and Exchange Commission, including the reports on Forms 10-K and
10-Q.
Actual results may differ materially from those projected.
These
forward-looking statements represent the Company`s judgment as of the date of
this release.
The Company disclaims, however, any intent or obligation to
update these forward-looking statements.
For further information, please contact:
Lori Parks, VP-Editorial,
Christian Pflaumer, Media Relations, or Linda Decker, VP-Investor Relations,
of Porter, LeVay & Rose, Inc., +1-212-564-4700, for BIOLASE Technology, Inc.;
or Jeffrey W. Jones, President and CEO of BIOLASE Technology, Inc.,
+1-949-361-1200.
SOURCE:
BIOLASE Technology, Inc.
SAN CLEMENTE, Calif., July 26 /PRNewswire/ -- BIOLASE Technology, Inc.
(Nasdaq: BLTI - news), announced today that it was granted a significant new patent
to use its HydroKinetic® technology for liposuction and other cosmetic soft
tissue procedures.
Since HydroKinetic technology uses a laser combined with
atomized water spray, BIOLASE expects the system in this patent to have
significant benefits over conventional liposuction, such as reduced bleeding,
less bruising, less trauma and less post-operative discomfort.
When compared
with other possible laser methods, HydroKinetics is expected to provide more effective cutting and removal of tissue without thermal damage, char or
potentially harmful smoke.
According to the American Society for Aesthetic Plastic Surgery,
lipoplasty (liposuction) was the most popular and fastest-growing surgical
cosmetic procedure, increasing 31% from 1999 to 2000 for a total of
376,633 procedures in the United States.
Cosmetic eyelid surgery ranked
second among surgical procedures, up 16% to 212,133 procedures.
Breast
augmentation was third, rising 6% to 203,310 procedures.
Ioana Rizoiu, the named inventor and vice president of clinical research
at BIOLASE, commented, ``This is both a device and method patent.
It is very
broad in regards to electromagnetic energy including the entire spectrum of
laser wavelengths and any and all sources of radiation, including all RF and
electrical sources.
This patent was filed as part of our overall, long-term
patent strategy and is only one of many others pending approval.``
Jeffrey W. Jones, BIOLASE CEO and president, explained, ``This innovative
patent expands the intellectual property of our HydroKinetic technology and is
an important addition to our overall patent portfolio.
This is another
important step to expand the intellectual property for the numerous fields and
applications of our core technology.
At this time, BIOLASE intends to keep
its current focus on dentistry.
We will explore the feasibility of alliances
and licensing for certain applications and expanded development.``
BIOLASE Technology, Inc. (http://www.biolase.com) is an advanced medical
technology company which possesses and develops advanced dental, cosmetic,
aesthetic and surgical products, including Waterlase(TM) (HydroKinetic®)
surgical cutting systems and other advanced laser and non-laser products for
the medical market.
The company`s products incorporate patented and
patent-pending technologies in the pursuit of painless surgery.
BIOLASE is
the world leader in painless hard and soft tissue dental laser technology.
The matters discussed in this news release include forward-looking
statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results
anticipated in such forward-looking statements.
Such risks, uncertainties and other factors include, but are not limited to, the effect of actions of third
parties, including governmental officials, the timely development and acceptance of new products, the impact of competitive products and pricing,
and other risks detailed from time-to-time in the Company`s filings with the
Securities and Exchange Commission, including the reports on Forms 10-K and
10-Q.
Actual results may differ materially from those projected.
These
forward-looking statements represent the Company`s judgment as of the date of
this release.
The Company disclaims, however, any intent or obligation to
update these forward-looking statements.
For further information, please contact:
Lori Parks, VP-Editorial,
Christian Pflaumer, Media Relations, or Linda Decker, VP-Investor Relations,
of Porter, LeVay & Rose, Inc., +1-212-564-4700, for BIOLASE Technology, Inc.;
or Jeffrey W. Jones, President and CEO of BIOLASE Technology, Inc.,
+1-949-361-1200.
SOURCE:
BIOLASE Technology, Inc.
Nachbörslich gingen immerhin noch 35000 für 6.35 über den Tisch.
Wie die damit optimaler das Fett absaugen sollen, ist mir noch unklar.
Aber das werden wir ja dann irgendmal bei einem der privaten Trivialsender sehen können.
von Thucko
Wie die damit optimaler das Fett absaugen sollen, ist mir noch unklar.
Aber das werden wir ja dann irgendmal bei einem der privaten Trivialsender sehen können.
von Thucko
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
+0,60 | |
-2,71 | |
-0,51 | |
+1.040,00 | |
+6,93 | |
-5,03 | |
+2,74 | |
-1,01 | |
-3,48 | |
+1,42 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
228 | ||
68 | ||
65 | ||
54 | ||
54 | ||
54 | ||
40 | ||
39 | ||
39 | ||
36 |